*  Expansion Therapeutics launches to target RNA with $55 million | January 8, 2018 Issue - Vol. 96 Issue 2 | Chemical &...
Nearly all small-molecule drugs bind to proteins, which are generally more structurally stable than RNA. Chemists have shunned ... RNA as a drug target for years, due to its floppy structure and the difficulty of designing drugs that selectively target one ... They list the use of fragment based screening by NMR and artificial intelligence to design their drugs. They are in Europe, but ... Expansion Therapeutics launches to target RNA with $55 million. Start-up will develop small molecules targeting RNA in the ...
  https://cen.acs.org/articles/96/i2/Expansion-Therapeutics-launches-target-RNA.html
*  DSpace@MIT: Computational engineering of small molecules to treat infectious diseases
Rational drug design of small molecules has led to the development of robust therapeutics that are currently used in the clinic ... and designing novel therapeutics. On-target mutations in infectious diseases often render inhibitors ineffective and are one of ... We use this improved receptor model to design novel analogs that are predicted to bind better than the parent compound. Lastly ... Computational engineering of small molecules to treat infectious diseases. Research and Teaching Output of the MIT Community. ...
  https://dspace.mit.edu/handle/1721.1/109667
*  C&EN's 2017 10 startups to watch
Most small-molecule drugs target proteins, but Arrakis is designing compounds that bind RNA molecules. Those that bind mRNA-the ... Relay Therapeutics. Probing protein motion to tackle tough drug targets. By Lisa M. Jarvis. At a glance. ... Design, make, test, repeat. Exscientia's drug discovery begins by feeding its AI algorithms mounds of existing data, which are ... Gilman doesn't expect all RNA molecules to selectively bind a drug, but he says that Arrakis wants to "find small molecules ...
  https://cen.acs.org/articles/95/i44/10-chemistry-startups-to-watch-2017.html
*  DNA-directed RNA interference - Wikipedia
Unlike small interfering RNA (siRNA) therapeutics that turn over within a cell and consequently only silence genes transiently ... A particularly useful variant is a multi-cassette (Figure 2b). Designed to express two or more shRNAs, they can target multiple ... The antisense species processed from the shRNA can bind to the target RNA and specify its degradation. shRNA constructs ... Tribetarna is a triple DNA cassette expressing three shRNA molecules that each separately target beta III tubulin and strongly ...
  https://en.wikipedia.org/wiki/DNA-directed_RNA_interference
*  Chemogenomics - Wikipedia
... is the systematic screening of targeted chemical libraries of small molecules against individual drug target families (e.g., ... Since a portion of ligands that were designed and synthesized to bind to one family member will also bind to additional family ... challenge of forward chemogenomics strategy lies in designing phenotypic assays that lead immediately from screening to target ... targeted therapeutics'. In forward chemogenomics, which is also known as classical chemogenomics, a particular phenotype is ...
  https://en.wikipedia.org/wiki/Chemogenomics
*  Kathleen Frey | LIU
... we can retrospectively examine the effects of drug target mutations on the binding of current therapeutics. Our understanding ... We use 3D structures of both protein-based targets and small molecules to design new compounds with improved affinity, efficacy ... In addition to designing antiviral agents, Dr. Frey has worked collaboratively with other scientists in Yale Chemistry and ... Computational Prediction of Drug Resistance: Drug resistance is a major problem for therapeutics used to treat cancer and ...
  http://www.liunet.edu/Pharmacy/Research/Faculty/Kathleen-Frey
*  Computational Resource for Drug Discovery - Wikipedia
... and siRNA/miRNA Drug design provides the resources important for designing drug inhibitors/molecules as lead optimization, ... It is a user friendly web server for the prediction of binding affinity of small chemical molecules against FAAH. KiDoQ: KiDoQ ... drug target N-acetylglucosamine-1-phosphate uridyltransferase (GLMU) protein. This is a potential drug target involved in ... developed for researchers working in the field of protein/peptide therapeutics. At present there is no single platform that ...
  https://en.wikipedia.org/wiki/Computational_Resource_for_Drug_Discovery
*  Molecules | Free Full-Text | Evolution of Complex Target SELEX to Identify Aptamers against Mammalian Cell-Surface Antigens |...
Nucleic acid aptamers (NAAs) represent a class of molecules able to meet this demand. In particular, aptamers, a class of small ... Such molecules should be simple in structure, yet stable enough for clinical applications. ... against almost any molecule. Since its introduction in 1990, in stages, SELEX technology has itself undergone several ... nucleic acid ligands that are composed of single-stranded modified/unmodified RNA/DNA molecules, can be evolved from a complex ...
  http://www.mdpi.com/1420-3049/22/2/215/htm
*  Regen BioPharma, Inc. Recruits Retinoid Experts Dr. Hinrich Gronemeyer, Dr. William S. Blaner, and Dr. Louise Purton to Serve...
This platform aims to design small molecules that can induce differentiation of cancer stem cells by designing ligands to ... ligands bind to their nuclear receptor target will provide us with invaluable insight during the preclinical stages of drug ... so we can develop small molecule therapeutics that circumvent the pitfalls of retinoic acid. Regen BioPharma is committed to ... in order to provide the Company with the expertise necessary to accelerate Regen's differentiation therapy small molecule drug ...
  http://www.marketwired.com/press-release/regen-biopharma-inc-recruits-retinoid-experts-dr-hinrich-gronemeyer-dr-william-s-blaner-otcbb-rgbp-2026505.htm
*  Carb Synthesis Sheds Light on Promising Tuberculosis Drug Target
The researchers found that a small fatty component at the starting end binds to the enzyme and helps it track the length of the ... Im Focus: Demonstration of a single molecule piezoelectric effect. Breakthrough provides a new concept of the design of ... In addition to providing insight into what may be a general mechanism for designing and building carbohydrates, the work gives ... insight into developing new therapeutics against TB. The GlfT2 enzyme is essential for bacterial survival and growth but has ...
  http://www.innovations-report.com/html/reports/medicine-health/carb-synthesis-sheds-light-promising-tuberculosis-134695.html
*  An Integrated Computational and Experimental Binding Study Identifies the DNA Binding Domain as the Putative Binding Site of...
... is as a potential drug target for cancer and inflammation. Strategies to block STAT3 dimerization ha.. ... 2015) Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppresses tumor growth, metastasis and STAT3 target ... This new class of STAT3 inhibitors may serve as important drug leads or probes for the design and studies of STAT3 DNA-binding ... This study was to identify novel STAT3 inhibitors that may be developed into probes or therapeutics, and to investigate their ...
  https://www.omicsonline.org/open-access/an-integrated-computational-and-experimental-binding-study-identifies-the-dna-binding-domain-as-the-putative-binding-site-of-novel-2169-0138-1000142.php?aid=86256
*  About | DeGrado Lab | UCSF
We also interact closely with the Small Molecule Discovery Center (SMDC) to design and develop novel small molecules with ... We are studying several transmembrane proteins and designing new ones in hopes of adding to this small but growing body of ... Molecules that target protein structures critical to the pathogenesis of HIV and Alzheimer's disease ... It has been possible to design functionally interesting proteins that bind redox-active cofactors, DNA, and transition metals. ...
  https://pharm.ucsf.edu/degrado/about
*  Combination Drug Delivery Approaches in Metastatic Breast Cancer
The journal serves researchers from academia and industry, and will publish articles ranging from basic biology of drug and ... Articles describing drug dosage forms will be considered. ... Journal of Drug Delivery is a peer-reviewed, Open Access ... Combination of Target-Specific Biologic Agent and Small Molecule Chemotherapeutic Agent. Small molecule chemotherapeutic agents ... Due to their nature monoclonal antibodies can be designed to bind to specific substances hence they are widely used for target ...
  https://www.hindawi.com/journals/jdd/2012/915375/
*  Molecular Partners - Wikipedia
Plückthun, A (2015). "Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy". ... Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical ... a validated immune checkpoint target) and VEGF-A, while also binding to human serum albumin. This tri-functional DARPin® is ... In January 2016, the Company announced plans for a Phase II trial of MP0250, a multi-DARPin® drug candidate targeting vascular ...
  https://en.wikipedia.org/wiki/Molecular_Partners
*  Molecules | Free Full-Text | Antimicrobial Peptides for Therapeutic Applications: A Review | HTML
In this review, we focus on small peptides, especially those with less than twelve amino acids, and provide an overview of the ... For instance, unusual amino acids or peptido-mimetics are introduced to avoid the proteolytic degradation and the design of ... modification of the drug-binding site in target proteins, and efflux of the drug from target cells [10]. Microorganisms can ... Fjell, C.D.; Hiss, J.A.; Hancock, R.E.; Schneider, G. Designing antimicrobial peptides: Form follows function. Nat. Rev. Drug ...
  http://www.mdpi.com/1420-3049/17/10/12276/htm
*  Drug design - Wikipedia
... will be designed that are complementary to the binding site of target. Small molecules (drugs) can be designed so as not to ... that drive ligand binding. Structure-based drug design attempts to use the structure of proteins as a basis for designing new ... and stability of these protein-based therapeutics have also been developed. The phrase "drug design" is to some extent a ... Ligand-based drug design (or indirect drug design) relies on knowledge of other molecules that bind to the biological target of ...
  https://en.wikipedia.org/wiki/Drug_design
*  Antibodies | Free Full-Text | Diving through Membranes: Molecular Cunning to Enforce the Endosomal Escape of Antibody-Targeted...
While numerous transport systems exist for ions and small molecules, the cytosolic uptake of larger biological molecules and in ... After binding and internalization, the antibody drug conjugates reach the endosomes. Thus, enforcing the endosomal escape of ... Inducing leakage of the plasma membrane is unfavorable since the target cell specificity mediated by the antibody would likely ... endosomal leakage inducing molecules such as saponins or monensin and physicochemical methods as represented by photochemical ...
  http://mdpi.com/2073-4468/2/2/209/htm
*  In vitro evaluation of functional interaction of integrin αvβ3 and matrix metalloprotease-2
Therapeutic strategies can be small molecule drugs, macromolecular drugs, prodrugs, or drug delivery systems, and the knowledge ... peptides binding integrin αvβ3 have also been successfully incorporated into drug delivery systems for targeting therapeutics ... Matrix Metalloproteases: Underutilized Targets for Drug Delivery. J. Drug Target. 2007;15(1):1-20. [PubMed] ... for designing prodrugs and delivery systems that require cleavage of MMP-2 substrate peptides for activating drug molecules ...
  http://pubmedcentralcanada.ca/pmcc/articles/PMC2790922/
*  JoVE | Peer Reviewed Scientific Video Journal - Methods and Protocols
While therapies that inhibit toxin binding/internalization have a small time window of administration, compounds that target ... and drug delivery. Designing materials based on the molecular-scale interactions between these proteins will help generate new ... where large libraries of small molecules are screened based on their ability to modulate therapeutic target function. Here we ... The reporter protein is designed so that its synthesis rate is constant whilst its degradation rate is determined by the degron ...
  https://www.jove.com/visualize/abstract/19898607/usa1-protein-facilitates-substrate-ubiquitylation-through-two
*  Campbell McInnes Ph.D. - College of Pharmacy | University of South Carolina
COBRE Center for Targeted Therapeutics. *Drug Design and Synthesis Core (DDSC). *Functional Genomics Core Facility ... Current research is directed towards the discovery of small molecule protein kinase inhibitors targeting signaling and cell ... Rather than blocking ATP binding, we are focused on the development of very selective inhibitors by targeting protein-protein ... The McInnes laboratory has developed the REPLACE strategy in order to more effectively target PPI's in general and have ...
  http://sc.edu/study/colleges_schools/pharmacy/faculty-staff/mcinnes_campbell.php
*  Frontiers | Targeting protein-protein interactions in complexes organized by A kinase anchoring proteins | Pharmacology
Furthermore, development of novel classes of small molecules involved in displacement of AKAP-bound signal molecules is now ... Furthermore, development of novel classes of small molecules involved in displacement of AKAP-bound signal molecules is now ... Targeting AKAP coordinated protein complexes with high-affinity peptidomimetics or small molecules to tease apart distinct ... Targeting AKAP coordinated protein complexes with high-affinity peptidomimetics or small molecules to tease apart distinct ...
  https://www.frontiersin.org/articles/10.3389/fphar.2015.00192/full
*  Marine Drugs | Free Full-Text | ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential | HTML
... describing their structure-activity relationships and potential as leads for the design of improved N-type therapeutics that ... Earlier in 2005, Prialt (Elan) or synthetic ω-conotoxin MVIIA, was the first ω-conotoxin to be approved by Food and Drug ... have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. ... Schroeder, C. I.; Smythe, M. L.; Lewis, R. J. Development of small molecules that mimic the binding of ω-conotoxin at the N- ...
  http://www.mdpi.com/1660-3397/4/3/193/htm
*  DARPin - Wikipedia
DARPins can be designed to act as receptor agonists, antagonists, inverse agonists, enzyme inhibitors, or simple target protein ... properties can be adjusted by fusion to half-life extending molecules, such as polyethylene glycol (PEG), or to DARPins binding ... Their small size (14-18 kDa) is thought to enable increased tissue penetration, and their high potency (. 100 g/L, and their ... DARPins and multi-DARPins can also be fused to non-DARPin elements, such as a toxin, to generate targeted therapeutics, and ...
  https://en.wikipedia.org/wiki/DARPin
*  Inte:Ligand - Wikipedia
"Efficient overlay of small organic molecules using 3D pharmacophores". Journal of Computer-Aided Molecular Design. 20 (12): 773 ... algorithms wrapped into KNIME extensions to be used for designing customized workflows related to computer aided drug design ... Malle, E.; Furtmüller P. G.; Sattler, W.; Obinger C. Myeloperoxidase: a target for new drug development? British Journal of ... "New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib". Molecular Cancer Therapeutics. 11 (8): 1693-1702. doi:10.1158/1535- ...
  https://en.wikipedia.org/wiki/Inte:Ligand
*  Gary Peltz | Stanford Medicine Profiles
From mouse genetics to human therapeutics CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT Peltz, G., Usuka, J. 2005; 8 (2): 253 ... Several small molecules, an antisense oligonucleotide, and gene therapeutic agents that inhibit NF-kappa b activation have been ... One T cell clone promiscuously recognized an epitope in the context of different HLA-DQ molecules. In addition, the binding of ... Guides that target regions with low nucleosome occupancy and high chromatin accessibility are clearly more effective. We also ...
  https://med.stanford.edu/profiles/gary-peltz